PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Faculty of Medicine, Universitas Padjadjaran /Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Electronic address: eddy.fadlyana@unpad.ac.id.\', \'Faculty of Medicine, Universitas Padjadjaran /Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.\', \'Faculty of Medicine, Universitas Padjadjaran /Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Electronic address: y.sofiatin@unpad.ac.id.\', \'PT. Bio Farma, Bandung Indonesia. Electronic address: rini.mulia@biofarma.co.id.\', \'PT. Bio Farma, Bandung Indonesia. Electronic address: lilis.setyaningsih@biofarma.co.id.\', \'PT. Bio Farma, Bandung Indonesia. Electronic address: fikrianti.surachman@biofarma.co.id.\', \'PT. Bio Farma, Bandung Indonesia. Electronic address: novilia@biofarma.co.id.\', \'Faculty of Medicine, Universitas Padjadjaran /Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Electronic address: imam.megantara@unpad.ac.id.\', \'National Institute of Health Research & Development, Jakarta, Indonesia.\', \'Sinovac Life Sciences Co., Ltd., Beijing, China. Electronic address: huyl@sinovac.com.\', \'Sinovac Life Sciences Co., Ltd., Beijing, China. Electronic address: gaoq@sinovac.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0264-410X(21)01255-X10.1016/j.vaccine.2021.09.052
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34620531
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all